Concepedia

Author

Udai Banerji

Institute of Cancer ResearchORCID

Also Known As

Banerji Udai, Banerji, U, U Banerji, U. Banerji, UDAI BANERJI, Udai Banerji

642

Publications

11.9K

Citations

51

H-Index

86

Concepts

All Affiliations

Institute of Cancer ResearchRoyal Marsden NHS Foundation TrustRoyal Marsden HospitalCancer Research UKThe Christie NHS Foundation Trust
UB

About

Udai Banerji is an author at Institute of Cancer Research specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

49

2.2K

2

Health Sciences

6

6

112

3

Engineering

2

2

84

4

Nursing

1

1

15

5

Allergy

1

1

18

Udai Banerji

×

119

Publications

7.6K

Citations

43

H-Index

YearCitations

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura,

The Lancet Oncology

2019

549

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

Udai Banerji, Anne O’Donnell, Michelle Scurr,

Journal of Clinical Oncology

2005

488

AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue,

Journal of Clinical Oncology

2017

315

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Timothy A. Yap, Brent O’Carrigan, Marina S. Penney,

Journal of Clinical Oncology

2020

237

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Udai Banerji, D. Ross Camidge, Henk M.W. Verheul,

Clinical Cancer Research

2010

209

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone

Paul A. Clarke, Isabelle Hostein, Udai Banerji,

Oncogene

2000

199

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

Simon Pacey, Richard H. Wilson, Mike Walton,

Clinical Cancer Research

2011

189

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

Jean‐Sébastien Frenel, Suzanne Carreira, Jane Goodall,

Clinical Cancer Research

2015

183

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer

Sarah Halford, Gareth J. Veal, Stephen R. Wedge,

Clinical Cancer Research

2023

177

Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

Udai Banerji, Michael I. Walton, Florence I. Raynaud,

Clinical Cancer Research

2005

164

Page 1